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A Ab bs st tr ra ac ct t
A germline mutation in the Von-Hippel Lindau (VHL) gene predisposes carriers to development of abundantly
vascularised tumours in the retina, cerebellum, spine, kidney, adrenal gland and pancreas. Most VHL patients
die from the consequences of cerebellar haemangioblastoma or renal cell carcinoma. The VHL gene is a tumour
suppressor gene and is involved in angiogenesis by regulation of the activity of hypoxia-inducible factor 1-α
(HIF1-α ). Clinical diagnosis of VHL can be confirmed by molecular genetic analysis of the VHL gene, which is
informative in virtually all VHL families. A patient with (suspicion for) VHL is an indication for genetic counselling
and periodical examination.
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I In nt tr ro od du uc ct ti io on n
A germline mutation in the Von-Hippel Lindau (VHL)
gene  predisposes  carriers  to  development  of
abundantly vascularised tumours in multiple organs.
These tumours may include haemangioblastoma in the
retina (also referred to as retinal angioma), cerebellum
and myelum, renal cell carcinoma (clear cell type),
phaeochromocytoma,  islet  cell  tumours  of  the
pancreas, and endolymphatic sac tumours, as well as
cysts  and  cystadenoma  in  the  kidney,  pancreas,
epididymis and broad ligament (Fig. 1) [1-3]. VHL
disease is an autosomal, dominant inherited tumour
syndrome with an estimated prevalence of 2-3 per
100,000 persons (OMIM #193300) [4]. At present,
metastases from renal cell carcinoma and neurological
complications from cerebellar haemangioblastoma are
the most common causes of death [5]. 
Using DNA diagnostics virtually all cases of classic
VHL  disease  are  identified,  enabling  early  and
presymptomatic diagnosis in families. Subsequently,
periodical clinical examination and advanced operation
techniques are likely to reduce both morbidity and
mortality in patients with VHL disease. 
D Di ia ag gn no os st ti ic c   c cr ri it te er ri ia a
In the presence of a positive family history, VHL disease
can be diagnosed clinically in a patient with at least oneH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 172
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typical VHL tumour. Typical VHL tumours are retinal, spinal
and  cerebellar  haemangioblastoma,  renal  cell
carcinoma, and phaeochromocytoma. Endolymphatic
sac tumours and multiple pancreatic cysts suggest
a positive carriership (in the presence of a positive VHL
family history), since they are uncommon in the general
population. In contrast, renal and epididymal cysts occur
frequently in the general population and are, as sole
manifestation, not reliable indicators for VHL disease. In
patients with a negative family history of VHL-associated
tumours, a diagnosis of VHL disease can also be made
when they exhibit two or more haemangioblastomas, or
a single haemangioblastoma in association with another
typical manifestation [3]. 
M Mo ol le ec cu ul la ar r   g ge en ne et ti ic cs s
The gene that, in mutated form, is responsible for the
disease is located on chromosome 3 (3p25-26) [6]. The
VHL  gene  is  a relatively  small  gene  that  covers
approximately 14,500 basepairs of genomic DNA. The
VHL gene encodes a ubiquitously expressed messenger
RNA of 4,700 nucleotides and the protein-coding region
is contained in three exons. Germline mutation analysis
has revealed two mutation hotspots that concur with
important functional domains of the VHL protein (Fig. 2). 
The  VHL  gene  is  a tumour  suppressor  gene
according to Knudson's 'two-hit' hypothesis [7]: for
a normal cell, inactivation of both copies of the VHL
gene is required to develop into a tumour cell. In
carriers of a VHL gene germline mutation, tumours tend
to occur multicentrically and bilaterally, and manifest
at a younger age than in patients without a VHL gene
germline mutation, where each of the two VHL gene
alleles  in  a cell  has  to  become  affected  by  an
independent hit at the somatic level. 
V VH HL L   p pr ro ot te ei in n
The VHL gene encodes a 213 amino acid protein
that does not closely resemble any other human protein.
The VHL protein resides predominantly in the cytoplasm
and is widely expressed in normal human tissues [8].
Strong expression is detected in target tissues of the
disease, such as cerebellar Purkinje cells, proximal and
distal renal tubules and exocrine pancreas. The VHL
protein is also expressed in organs not at risk for the
disease, such as the pituitary gland, colon and thyroid.
The protein plays a vital role in embryonic development.
Foetal mice deprived of both copies of the VHL gene are
not viable. In human embryos, the VHL protein is
expressed in all three germ layers [9]. 
The well-vascularised phenotype of VHL tumours
suggests that inactivation of the VHL gene induces either
upregulation of an angiogenic factor or downregulation
of an inhibitor of angiogenesis. In VHL-associated
haemangioblastoma and renal cell carcinoma, various
proteins  that  are  involved  in  angiogenesis  are
upregulated. These angiogenic proteins include vascular
endothelial growth factor (VEGF), plasminogen activator
inhibitor 1 (PAI-1) and erythropoietin [10-12]. The genes
coding for these proteins have in common that they are
regulated  by  hypoxaemia.  During  hypoxaemia
a transcription factor, hypoxia-inducible factor (HIF)-1α ,
binds to the promoters of these genes and stimulates
their transcription [10]. In normoxic conditions HIF-1α
binds to the β -domain of the VHL protein (Fig. 3). The
α -domain of the VHL protein binds to Elongin C C, which
is connected with Elongin B B in a multi-protein complex
(Fig. 3) [13]. This complex targets the HIF-1α substrate
for degradation in a proteasome via a process called
ubiquitination. Consequently, excessive blood vessel
formation may occur when hypoxia-inducible proteins
are not properly degraded. In other words, in cells lacking
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F Fi ig g. .   2 2. .   Functional domains of the VHL protein and distribution of germline mutations (from VHL database) [22]. Hotspots for mutations are
readily visible at amino acids 67-117, hypoxia-inducible factor (HIF)-1α binding domain (in the ß-domain) and 157-170, Elongin C (EloC)
binding domain (in the α -domain). Copyright 2003, The Endocrine Society [16]
wild-type VHL protein, degradation of HIF-1α is impaired
and thus those cells behave as if they were deprived of
oxygen. In addition to the regulation of HIF-1α , the VHL
protein has been demonstrated to interact with fibronectin
and urokinase, which are required for extracellular matrix
formation [11, 14]. 
N Na at tu ur ra al l   h hi is st to or ry y
The relationship between the presence of a VHL
germline mutation and the occurrence of one or more
VHL-related tumours is a well-established observation in
the literature. Only scarce evidence is provided for reduced
or even non-penetrance of some VHL germline mutations
[4]. The mean prevalence of VHL-associated tumours is
depicted in Figure 1. Generally, VHL gene germline
mutation carriers present tumours at a relatively young
age. However, the age at diagnosis also depends on the
intensity of pursuit. The mean age at diagnosis (with
intervals) for VHL tumours are: retinal haemangioblastoma
25 years (1-68), phaeochromocytoma 30 years (5-56),
cerebellar haemangioblastoma 30 years (9-78), and renal
cell carcinoma 35-40 years (15-69) [1-5]. 
Based upon clinical expression of the disease, VHL
disease has been divided into four subtypes, with a central
role for phaeochromocytoma (Table 1). Patients with VHL
type 1 have no phaeochromocytomas. Type 2 families
have phaeochromocytomas and are divided into subtypes
with a low (2A) or high risk (type 2B) of renal cell
carcinoma,  while  type  2C  families  present  with
phaeochromocytoma only. In addition to evidence for
interfamilial variability, also intrafamilial variability is a well-
observed characteristic in VHL disease. This observation
indicates that other genetic ('modifier' genes) and/or
environmental  factors  are  involved  in  the  clinical
manifestations  of  VHL  germline  mutations  [15].
Apparently, there is no simple relationship between
a germline  mutation  in  the  VHL  gene  and  the
manifestation (age of onset and type) of VHL-related
tumours. Moreover, these observations do not enable
individualised monitoring of VHL disease. 
P Pa at th ho op ph hy ys si io ol lo og gy y
Whereas VHL disease manifests itself as an autosomal
dominant trait, it can be considered as a recessive trait
at the cellular level. Similar to other hereditary tumours
caused by germline inactivation of a tumour suppressor
gene, VHL tumours arise by a loss of the wild-type VHL
allele, while maintaining the mutated allele. Such loss of
heterozygosity (LOH, caused by deletion, non-disjunction,
somatic recombination, etc.) at the VHL locus has beenH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 174
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F Fi ig g. .   3 3. .   The VHL protein and oxygen-dependent ubiquitination of the hypoxia-inducible factor (HIF)-1α . The VHL protein contains two functional
domains: alpha (α ) and beta (β ). The α -domain of the VHL protein binds to Elongin C, which is connected with Elongin B in a multi-protein
complex consisting of Cul2, Rbx1 and E2 ubiquitin conjugating enzyme (E2). The β -domain directly binds the substrate, HIF-1α . The VHL
protein directs, depending on the amount of available oxygen, the breakdown (ubiquitination) of HIF-1α in the proteasome. In normoxic
circumstances, HIF-1α is hydroxylated and binds to an intact VHL protein and is ubiquitinated in the proteasome (left). During hypoxic circumstances
HIF-1α is not hydroxylated. The non-hydroxylated HIF-1α does not bind to the VHL protein and accumulates (right). In the case of a defect or
absent VHL protein, HIF-1α also accumulates. Subsequently, genes that are regulated by HIF-1α , like vascular endothelial growth factor (VEGF)
and erythropoietin (Epo), are upregulated, leading to (neo) angiogenesis and tumour growth. Copyright 2003, The Endocrine Society [16]
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demonstrated in most VHL disease associated tumours.
Apart  from  LOH,  other  mechanisms  of  somatic
inactivation of the VHL gene (point mutations, promoter
hypermethylation) have also been observed in these
tumours.  In  non-familial  (VHL-related)  tumours,
tumourigenesis is thought to be initiated by independent
somatic alteration of both alleles of the VHL tumour
suppressor gene. Somatic VHL gene mutations and allele
loss are indeed frequent events in sporadic clear cell renal
cell carcinoma and sporadic haemangioblastoma, but
are uncommon in sporadic (i.e. non-tumour syndrome
associated) phaeochromocytoma. 
So far, there is no evidence for downregulation of
an inhibitor of angiogenesis in VHL tumourigenesis. The
abundant vascularisation of haemangioblastoma and
renal cell carcinoma can be readily explained with the
HIF-1α and ubiquitination theory as described above.
Loss of VHL function reduces HIF-1α degradation and
increases VEGF expression, which leads in turn to
angiogenesis. In general, protein truncating mutations
and missense mutations in the β -domain of the VHL
protein, predicting a loss of function, seem to be
associated with VHL type 1 (Fig. 2 and Table 1). 
In contrast, putative gain of function mutations are
associated with VHL type 2C, involving non-excessively
vascularised phaeochromocytoma only [14]. VHL type
2C families are predominantly associated with specific
missense mutations, notably in the α -domain. In type 2A
and type 2B, mutations hamper either the binding to
ElonginC by the α -domain of VHL or the capture of target
proteins by the β -domain of VHL. Consequently, such
target proteins (e.g. HIF-1α ) cannot be properly degradedH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 175
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T Ta ab bl le e   2 2. .   Persons eligible for VHL gene germline mutation analysis
1. A patient with classic VHL disease (meeting clinical diagnostic criteria) and/or first degree family members 
2. A person from a family in which a germline VHL gene mutation has been identified (presymptomatic test) 
3. A VHL-suspected patient, i.e.: 
– multicentric VHL tumours in one organ, 
– bilateral VHL tumours, 
– two or more VHL organ systems affected, 
– one VHL-associated tumour at a young age (i.e. <50 years for haemangioblastoma and phaeochromocytoma 
and <30 years for renal cell carcinoma) 
4. A patient from a family with haemangioblastoma, renal cell carcinoma or phaeochromocytoma only 
T Ta ab bl le e   1 1. .   Genotype-phenotype correlation for von Hippel-Lindau disease and possible responsible pathophysiological mechanism
T Ty yp pe e   V VH HL L T Ty yp pe e   o of f   V VH HL L   g ge en ne e R Re et ti in na al l    C CN NS S    R RC CC C P PH HA AE EO O M Me ec ch ha an ni is sm ms s   f fo or r   V VH HL L   
g ge er rm ml li in ne e   m mu ut ta at ti io on n H HA AB B H HA AB B m me ed di ia at te ed d   t tu um mo ou ur ri ig ge en ne es si is s
1 missense + + + – loss of function (i.e. HIF-1α degradation)
microdeletions
insertions 
splice site 
nonsense 
large deletions 
2A missense + + – + gain of function (PHAEO) 
2B missense + + + + loss of function (HAB+RCC) 
2C missense – – – + gain of function, fibronectin
HAB, haemangioblastoma; CNS, central nervous system; RCC, renal cell carcinoma (clear cell type); PHAEO, phaeochromocytoma; HIF, hypoxia-inducible factor; 
+, tumour present; -, tumour absent
in the proteasome [10]. Phenotypes 2A and 2B have,
next to a low or high risk of renal cell carcinoma,
respectively, development of both haemangioblastoma
and phaeochromocytoma. The co-occurrence of these
two kinds of tumours is a consequence of a single amino
acid substitution in the VHL protein but is putatively caused
by opposing tumourigenic mechanisms (i.e. gain of
function and loss of function). Previously, we have
hypothesized that this apparent discrepancy might be
explained by tissue-specific VHL dosage effects, possibly
in combination with tissue-specific involvement of other
proteins mediating HIF1-α degradation [16]. 
M Mu ut ta at ti io on n   d de et te ec ct ti io on n
VHL  gene  germline  mutations  are  detected  in
virtually all classic families with more than one affected
family member, or classic sporadic patients with multiple
VHL-related tumours [17]. Moreover, VHL gene germline
mutations are identified in 4% of patients with apparently
sporadic haemangioblastoma, in 1.6 % with renal cell
carcinoma and in 3% to 9% with phaeochromocytoma
[18-21]. So, VHL gene germline mutations are not only
identified in patients who do meet clinical diagnostic
criteria, but also in patients with one or more VHL
tumour and/or without a negative family history. This
may occur when there is 1) incomplete family history
data; 2) non-penetrance of a germline mutation in one
of the parents; 3) a 'de novo' mutation. De novo
mutations occur in approximately 20% of the identified
VHL gene germline mutation carriers [4]. 
The  mutation  spectrum  is  heterogeneous,  with
mutations scattered throughout most of the VHL gene
(Fig. 2) [22]. Missense mutations are found in 40% of the
families with an identified VHL gene germline mutation
[17]. Microdeletions (1-18 nucleotides), insertions (1-8
nucleotides), splice site and nonsense mutations, all
predicted to lead to a truncated protein, are found in
30%  of  the  families.  Large  deletions  (deletions
encompassing the entire gene) account for the remaining
30% of the VHL gene germline mutations. Since the size
of the protein-encoding region of the VHL gene is small,
it seems justified to perform screening for point mutations
for VHL always by direct nucleotide sequence analysis of
the entire protein-encoding region and splice-junctions.
Deletions are readily detected with 'Southern blotting' andH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 176
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T Ta ab bl le e   3 3. .   VHL protocol for periodic clinical surveillance
I In nv ve es st ti ig ga at ti io on n A Ag ge e, ,   f fr re eq qu ue en nc cy y
– patients' history, – from 10 years old, annually
– physical examination, blood pressure – from 10 years old, annually 
– biochemical blood tests – from 10 years old, annually 
– 24-h urine tests (catecholamines and metanefrines)* – from 10 years old, annually 
– ophthalmological examination – from 5 years old, annually
– upper abdominal ultrasound – from 10 years old, annually
– MRI (with gadolinium) cerebellum and myelum – from 15 years old, two-yearly**
– MRI upper abdomen – when indicated***
– MRI inner ear – when indicated****
– audiogram – when indicated****
– neurological examination – when indicated
*Accumulating evidence suggests that measurements of plasma-free metanephrines or urinary-fractionated metanephrines (normetanephrine and metanephrine 
separately) are the most sensitive tests for diagnosis, and are the most suitable for reliable exclusion of phaeochromocytoma [27]. These tests are particularly
indicated in VHL type 2. 
**Radiosurgical techniques have been developed that enable presymptomatic treatment of solid cerebellar haemangioblastoma [26], which may justify (more
frequent) periodical surveillance for these tumours. 
***When an MRI of the myelum is made every two years it is recommended to image the upper abdominal organs simultaneously. In this way the upper
abdomen is monitored with ultrasound and MRI in alternate years. 
****When an endolymphatic sac tumour (ELST) is suspected; i.e. hearing loss/deafness, tinnitus, or vertigo [2]. 
'Fluorescence In Situ Hybridization' (FISH) [17], and more
recently  using  'Multiple  Ligation-dependent  Probe
Amplification' (MLPA, www.mrc-holland.com). 
Criteria for DNA analysis are presented in Table 2.
Both clinical geneticists and consulting physicians may
request genetic testing in a symptomatic patient for the
confirmation  of  a clinical  diagnosis.  However,
consultation of a clinical geneticist is indicated before
a genetic test is to be performed because a molecular
genetic diagnosis may have consequences for both the
index patients and their family members. Moreover,
the experience of a clinical geneticist may be needed
for a correct interpretation of the test result. 
Because genetic counselling entails many aspects,
such as information about psychological and social
consequences, presymptomatic tests should preferably
be performed by clinical geneticists. 
P Pr ra ac ct ti ic ca al l   g gu ui id de el li in ne es s
Clinical monitoring (Table 3) should be primarily
organized around those VHL patients who have tested
positive for a VHL gene germline mutation. In addition,
the following persons should be monitored: first- and
second-degree family members in a VHL family without
an  identified  germline  mutation;  first-  and
second-degree family members that decline a DNA test;
patients (and first-degree family members) with a typical
VHL tumour and features that suggest the presence of
a germline mutation (i.e. the presence of multi-centric
or bilateral tumours, involvement in more than one
organ, a suspected family history and young age at
diagnosis) [23]. With the involvement of many organs
in VHL disease, it is of utmost importance that periodic
monitoring is carried out in a well-co-ordinated,
multidisciplinary team of physicians. On the basis of
present knowledge of genotype-phenotype correlations
in VHL disease, periodic monitoring cannot yet be
invidualised. However, regarding phaeochromcyotoma,
we feel periodic monitoring could be less frequent in
VHL type 1 and more frequent in VHL type 2. 
So far, only a small number of guidelines for the
treatment  of  VHL-associated  tumours  have  been
developed. Most commonly, a choice is made between
conservative policy (surveillance of tumours) and
surgery. A good example in this dilemma is renal cell
carcinoma. Options for treatment range from bilateral
nephrectomy, nephron-sparing surgery to follow-up
investigations only [24]. If both kidneys are affected
with multiple cysts and tumours, a difficult decision has
to  be  made  between  radical  nephrectomy  or
nephron-sparing  surgery.  Whenever  feasible,H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 177
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nephron-sparing surgery is performed in order to
maintain renal function as long as possible. 
The other potentially life-threatening tumour in VHL
disease  is  the  cerebellar  haemangioblastoma.
Haemangioblastomas are regarded as benign and
slow-growing tumours that do not normally invade the
surrounding brain [25]. However, complications may arise
due to the tumour's tendency to form expanding cysts.
Cerebellar shift may lead to herniation of the cerebellar
tonsils through the foramen magnum and subsequently
elevated or even life-threatening intracranial pressure.
Hydrocephalus may result in rapid decompensation with
papilloedema. Cerebellar haemangioblastomas remain
a major cause of morbidity and mortality in VHL patients
[5]. The standard treatment is complete microsurgical
removal, aided if necessary by preoperative embolisation
to reduce the tumour's vascularity. A new technique,
stereotactic radiosurgery, offers the possibility of tackling
multiple cerebellar lesions in a single treatment, which is
particularly important in VHL patients [26]. Radiosurgery
shrinks, or stops the growth of, small- or medium-sized
(i.e. smaller than 3 cm) solid haemangioblastomas.
Adjoining cysts, however, do not respond to radiosurgery
and require later, sometimes repeated, evacuation. 
Since early detection, periodic clinical surveillance
and timely treatment of VHL patients lead to a better
prognosis, information on the possibility of DNA analysis
has to be provided to all family members. For privacy
reasons, it is not allowed for health care workers to
contact family members of VHL patients directly. With
information  brochures  (spread  via  the  patient  or
informed family members) persons at risk for VHL
disease can be informed and advised to seek genetic
counselling themselves. In this way they have a free
choice for themselves, whether they (or their offspring)
want to be tested. Patients can turn to VHL support
groups for support in emotional distress, information,
and advice on social issues (see: www.vhl.org). 
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